Milestones, programmes and the science behind affordable, scalable cancer monitoring — straight from the 2Strands newsroom.
The pre-seed round will accelerate development of 2Strands' proprietary rare variant enrichment technology — bringing accurate, affordable MRD monitoring closer to the clinic.
Read the full story →2Strands joins a select cohort gaining structured access to the US clinical and commercial landscape.
Read more →Selected for the APAC accelerator — mentorship and partnerships to scale across the region.
Read more →Awarded the Illumina for Startups grant — sequencing support to advance our enrichment chemistry.
Read more →Our investors share our vision of catching cancer recurrence before it takes hold.
Read more →Working with NCCS clinicians to validate MRD monitoring in real-world patient cohorts.
Read more →Internal data shows enrichment concentrates low-frequency mutations ahead of sequencing.
Read more →